Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) announced the pricing of its public offering with expected gross proceeds of approximately $4 million before fees and expenses. The offering consists of 2,962,963 shares of common stock and 2,962,963 warrants, with each share priced at $1.35.

The warrants carry an exercise price of $1.35 per share. Sonoma Pharmaceuticals granted Dawson James Securities a 45-day option to purchase up to 15% of the shares or warrants sold to cover over-allotments.

The offering is scheduled to close on April 27, 2026, subject to customary closing conditions. The company plans to use net proceeds for general corporate purposes, including working capital.

Dawson James Securities serves as sole bookrunner for the offering. A registration statement on Form S-1 related to the securities offering was filed with the Securities and Exchange Commission and declared effective on April 23, 2026.

Sonoma Pharmaceuticals develops and produces stabilized hypochlorous acid products for applications including wound care, eye care, dermatological conditions, and animal health care. The company sells products directly or through partners in 55 countries, with its principal office in Boulder, Colorado, and manufacturing operations in Guadalajara, Mexico.